Finance Portfolio Enabler (R&D )

at  Genentech

THE POSITION

Doubling down on investment in R&D doesn‘t automatically lead to increased outcomes and patient benefits. In fact, the last two decades the Pharma Industry has seen higher R&D costs, a reduced rate of approvals, and fewer commercial opportunities for new drugs. Moreover, in an environment characterized by disruption, we need high financial flexibility to pivot quickly as new opportunities emerge. In other words, we cannot do more of the same and expect better results.
We are challenging our status quo across our R&D units with investments aimed at fundamentally changing how we benefit patients. Whether through our new Institute of Human Biology or incorporation of Large Language Models into our drug discovery efforts, we believe these bets will help us thrive over the next five years and in the coming decades. Of course, any investment in innovation within our industry comes with high risk and extended timelines. Roche’s/ Genentech’s success depends on the success of our R&D, and we cannot succeed in R&D unless we constantly reassess how we allocate our resources, from cutting failing projects in favor of thriving ones to seeking early signals around our long-term investments to make sure we are on the right track.
Finance’s role here has never been more important, and it is imperative that we bring our enterprise lens to the conversation to enable optimal resource use and smart investment decisions.

• Leading a team of senior finance professionals to maximize impact and deliver value in a global network, including bulging a strong and diverse talent pipeline across the Network and all sites and foster diverse talent flow
• Facilitating and driving key Outcomes within the R&D Finance network, specifically with a cross-Portfolio lens, including developing a cross-R&D perspective and further improving transparency on cross-R&D Portfolio investment
• Representing Finance in the Portfolio Advisory Team (PAT) and enabling the Pharma Portfolio Team (PPT) to make strategic decisions at the enterprise level - including ensuring alignment with Roche’s “One Pharma” approach, setting cross-pharma E2E strategic direction, establishing the Target Portfolio, aligning R&D priorities, and balancing the overall risk/reward profile of the portfolio - from a Finance Lens.
• Being a catalyst for creating connections across the whole Finance network to enable effective collaboration leveraging all the strengths of Finance
• Enabling implementation of R&D Excellence Portfolio-related solutions as well as required adjustments to the operating model
• Build a strong partnership with the R&D Finance Functional Enabler, Enterprise Center of Excellence (eCoE) Enabler and R&D Finance Network Enabler to collaborate and identify opportunities for cross-R&D perspectives and optimization